<DOC>
	<DOCNO>NCT00005847</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . Biological therapy use different way stimulate immune system stop cancer cell grow . It yet know treatment regimen effective treat metastatic prostate cancer . PURPOSE : Randomized phase II trial compare effectiveness combination chemotherapy chemotherapy plus biological therapy treat patient progressive metastatic prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>Chemotherapy With Without Biological Therapy Treating Patients With Metastatic Prostate Cancer That Has Not Responded Hormone Therapy</brief_title>
	<detailed_description>OBJECTIVES : - Compare effect estramustine , mitoxantrone , vinorelbine v isotretinoin , interferon alfa , paclitaxel PSA response patient metastatic hormone-refractory prostate cancer . - Determine toxic effect regimen patient population . - Determine effect regimen pain , fatigue , quality life patient . - Determine objective response rate among subset patient bidimensionally measurable disease regimen treatment . - Determine effect regimen peripheral blood mononuclear cell BCL-2 patient . OUTLINE : This randomize , multicenter study . Patients stratify accord disease ( measurable v nonmeasurable elevated PSA ) . Patients randomize one two treatment arm . - Arm I : Patients receive vinorelbine IV 10 minute day 2 9 follow mitoxantrone IV 10 minute day 2 . Oral estramustine administer every 12 hour day 1-5 . Courses repeat every 3 week absence unacceptable toxicity , disease progression , administration maximum cumulative dose mitoxantrone . - Arm II : Patients receive oral isotretinoin interferon alfa subcutaneously day 1 2 paclitaxel IV 1 hour day 2 weekly 6 week . Courses repeat every 8 week absence unacceptable toxicity disease progression . Quality life assess baseline , day 2 course 2 , 4 , 6 ( arm I ) , day 22 course 1 day 1 course 2 3 ( arm II ) , completion treatment . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 70-114 patient ( 35-57 per arm ) accrue study within 14-23 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Evidence progressive metastatic disease ( e.g. , bone , pelvic mass , lymph node , liver lung metastasis ) Radiologic evidence hydronephrosis constitute evidence metastatic disease Must elevate serum alkaline phosphatase PSA level evidence disease If bone metastasis ( i.e. , lack soft tissue disease ) , must PSA level least 20 ng/mL If soft tissue metastasis and/or visceral disease , must either bidimensionally measurable disease PSA level least 20 ng/mL Must prior bilateral orchiectomy primary hormonal therapy ( e.g. , estrogen therapy LHRH blocker plus flutamide ) evidence treatment failure No carcinomatous meningitis brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC least 4,000/mm^3 Granulocyte count least 2,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : See Disease Characteristics Bilirubin great 1.5 mg/dL SGOT/SGPT great 2 time upper limit normal Renal : Creatinine great 2.0 mg/dL OR Creatinine clearance least 50 mL/min Cardiovascular : No active angina pectoris No New York Heart Association class III IV heart disease No myocardial infarction within past 6 month No deep venous thrombosis LVEF least 50 % MUGA Other : Fertile patient must use effective contraception 1 month study Prior malignancy allow provide curatively treated disease free appropriate time period specific cancer No serious medical illness active infection would preclude protocol therapy No concurrent prolong exposure sunlight No concurrent alcohol consumption PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy , include neoadjuvant chemotherapy singleagent estramustine Endocrine therapy : See Disease Characteristics If prior bilateral orchiectomy , must continue LHRH agonist therapy ( e.g. , depot leuprolide goserelin ) At least 4 week since prior flutamide flutamide evidence progressive disease At least 6 week since prior bicalutamide evidence progressive disease Radiotherapy : More 4 week since prior radiotherapy No prior strontium chloride Sr 89 , samarium Sm 153 lexidronam pentasodium , radioisotope therapy Surgery : See Disease Characteristics Other : Recovered toxic effect due prior treatment prostate cancer No concurrent milk , milk product , antacid , calciumcontaining drug , food estramustine ( arm I ) No concurrent vitamin supplement contain vitamin A ( arm II )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>